Literature DB >> 28437538

Effects of Diagnosis by Newborn Screening for Cystic Fibrosis on Weight and Length in the First Year of Life.

Daniel H Leung1, Sonya L Heltshe2, Drucy Borowitz3, Daniel Gelfond4, Margaret Kloster5, James E Heubi6, Michael Stalvey7, Bonnie W Ramsey2.   

Abstract

Importance: Since the implementation of universal newborn screening (NBS) for cystic fibrosis (CF), the timing and magnitude of growth deficiency or its association with correlates of disease among infants with CF who underwent NBS has not been well described. Objective: To examine incremental weight gain, linear growth, and clinical features in the first year of life among infants with CF who underwent NBS. Design, Setting, and Participants: The Baby Observational and Nutrition Study (BONUS), a multicenter, longitudinal, observational cohort study, was conducted during regular CF clinic visits in the first 12 months of life at 28 US Cystic Fibrosis Foundation-accredited Care Centers from January 7, 2012, through May 31, 2015. Participants included 231 infants younger than 3.5 months who underwent NBS and had confirmed CF, with a gestational age of at least 35 weeks, birth weight of at least 2.5 kg, and toleration of full oral feeds. Of these, 222 infants (96.1%) had follow-up beyond 6 months of age and 215 (93.1%) completed 12 months of follow-up. Exposure: Cystic fibrosis. Main Outcome and Measures: Attained weight and length for age and World Health Organization normative z scores at ages 1 to 6 and 8, 10, and 12 months (defined a priori).
Results: Of the 231 infants enrolled, 110 infants (47.6%) were female and 121 (52.4%) were male, with a mean (SD) age of 2.58 (0.69) months. BONUS infants had lower than mean birth weights (mean z score, -0.15; 95% CI, -0.27 to -0.04) and higher birth lengths (mean z score, 0.44; 95% CI, 0.26 to 0.62). They achieved normal weight by 12 months, a significant improvement over a prescreening cohort of newborns with CF from 20 years before the contemporary cohort (mean z score increase, 0.57; 95% CI, 0.37-0.77). However, length was lower than the mean at 12 months (mean z score, -0.56; 95% CI, -0.70 to -0.42). Only 30 infants (13.6%) were at less than the 10th percentile of weight for age, whereas 53 (23.9%) were at less than the 10th percentile of length for age at more than half their visits. Male sex, pancreatic insufficiency, meconium ileus, histamine blocker use, and respiratory Pseudomonas aeruginosa infection were associated with lower weight or length during the first year. Insulinlike growth factor 1 levels were significantly lower among low-length infants. Persistently low-weight infants consumed significantly more calories, and weight and length z scores were negatively correlated with caloric intake. Conclusions and Relevance: Since initiation of universal NBS for CF, significant improvement has occurred in nutritional status, with normalization of weight in the first year of life. However, length stunting remains common.

Entities:  

Mesh:

Year:  2017        PMID: 28437538      PMCID: PMC5731827          DOI: 10.1001/jamapediatrics.2017.0206

Source DB:  PubMed          Journal:  JAMA Pediatr        ISSN: 2168-6203            Impact factor:   16.193


  35 in total

1.  An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation.

Authors:  V Tangpricha; A Kelly; A Stephenson; K Maguiness; J Enders; K A Robinson; B C Marshall; D Borowitz
Journal:  J Clin Endocrinol Metab       Date:  2012-03-07       Impact factor: 5.958

Review 2.  Growth and the Growth Hormone-Insulin Like Growth Factor 1 Axis in Children With Chronic Inflammation: Current Evidence, Gaps in Knowledge, and Future Directions.

Authors:  S C Wong; R Dobie; M A Altowati; G A Werther; C Farquharson; S F Ahmed
Journal:  Endocr Rev       Date:  2015-12-31       Impact factor: 19.871

3.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Authors:  Claire E Wainwright; J Stuart Elborn; Bonnie W Ramsey; Gautham Marigowda; Xiaohong Huang; Marco Cipolli; Carla Colombo; Jane C Davies; Kris De Boeck; Patrick A Flume; Michael W Konstan; Susanna A McColley; Karen McCoy; Edward F McKone; Anne Munck; Felix Ratjen; Steven M Rowe; David Waltz; Michael P Boyle
Journal:  N Engl J Med       Date:  2015-05-17       Impact factor: 91.245

4.  Use of World Health Organization and CDC growth charts for children aged 0-59 months in the United States.

Authors:  Laurence M Grummer-Strawn; Chris Reinold; Nancy F Krebs
Journal:  MMWR Recomm Rep       Date:  2010-09-10

5.  Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease.

Authors:  D S Donovan; A Papadopoulos; R B Staron; V Addesso; L Schulman; C McGregor; F Cosman; R L Lindsay; E Shane
Journal:  Am J Respir Crit Care Med       Date:  1998-06       Impact factor: 21.405

Review 6.  The cystic fibrosis gene and relationships to clinical status.

Authors:  P W Campbell; J A Phillips
Journal:  Semin Respir Infect       Date:  1992-09

7.  Growth of human milk-fed and formula-fed infants with cystic fibrosis.

Authors:  K E Holliday; J R Allen; D L Waters; M A Gruca; S M Thompson; K J Gaskin
Journal:  J Pediatr       Date:  1991-01       Impact factor: 4.406

8.  Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.

Authors:  Drucy Borowitz; Karen A Robinson; Margaret Rosenfeld; Stephanie D Davis; Kathryn A Sabadosa; Stephanie L Spear; Suzanne H Michel; Richard B Parad; Terry B White; Philip M Farrell; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

9.  A revised measure of acute pain in infants.

Authors:  A Taddio; I Nulman; B S Koren; B Stevens; G Koren
Journal:  J Pain Symptom Manage       Date:  1995-08       Impact factor: 3.612

10.  Genetic modifiers of liver disease in cystic fibrosis.

Authors:  Jaclyn R Bartlett; Kenneth J Friedman; Simon C Ling; Rhonda G Pace; Scott C Bell; Billy Bourke; Giuseppe Castaldo; Carlo Castellani; Marco Cipolli; Carla Colombo; John L Colombo; Dominique Debray; Adriana Fernandez; Florence Lacaille; Milan Macek; Marion Rowland; Francesco Salvatore; Christopher J Taylor; Claire Wainwright; Michael Wilschanski; Dana Zemková; William B Hannah; M James Phillips; Mary Corey; Julian Zielenski; Ruslan Dorfman; Yunfei Wang; Fei Zou; Lawrence M Silverman; Mitchell L Drumm; Fred A Wright; Ethan M Lange; Peter R Durie; Michael R Knowles
Journal:  JAMA       Date:  2009-09-09       Impact factor: 56.272

View more
  30 in total

1.  GH-IGF-1 Axis in Children with Cystic Fibrosis.

Authors:  Sara Pagani; Elena Bozzola; Gloria Acquafredda; Vito Terlizzi; Valeria Raia; Fabio Majo; Alberto Villani; Mauro Bozzola
Journal:  Clin Med Res       Date:  2019-08-28

2.  Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening.

Authors:  Daniel Gelfond; Sonya L Heltshe; Michelle Skalland; James E Heubi; Margaret Kloster; Daniel H Leung; Bonnie W Ramsey; Drucy Borowitz
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-04       Impact factor: 2.839

3.  Age and environmental exposures influence the fecal bacteriome of young children with cystic fibrosis.

Authors:  Brett R Loman; Chandra L Shrestha; Rohan Thompson; Judith A Groner; Asuncion Mejias; Kathryn L Ruoff; George A O'Toole; Michael T Bailey; Benjamin T Kopp
Journal:  Pediatr Pulmonol       Date:  2020-04-10

4.  Does exclusion of extreme reporters of energy intake (the "Goldberg cutoffs") reliably reduce or eliminate bias in nutrition studies? Analysis with illustrative associations of energy intake with health outcomes.

Authors:  Keisuke Ejima; Andrew W Brown; Dale A Schoeller; Steven B Heymsfield; Erik J Nelson; David B Allison
Journal:  Am J Clin Nutr       Date:  2019-11-01       Impact factor: 7.045

5.  Urinary metabolomics reveals unique metabolic signatures in infants with cystic fibrosis.

Authors:  B T Kopp; E Joseloff; D Goetz; B Ingram; S L Heltshe; D H Leung; B W Ramsey; K McCoy; D Borowitz
Journal:  J Cyst Fibros       Date:  2018-11-23       Impact factor: 5.482

6.  In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis.

Authors:  Xingshen Sun; Yaling Yi; Ziying Yan; Bradley H Rosen; Bo Liang; Michael C Winter; T Idil Apak Evans; Pavana G Rotti; Yu Yang; Jaimie S Gray; Soo Yeun Park; Weihong Zhou; Yulong Zhang; Shashanna R Moll; Lisa Woody; Dao M Tran; Licong Jiang; Annelotte M Vonk; Jeffrey M Beekman; Paul Negulescu; Fred Van Goor; Dennis F Fiorino; Katherine N Gibson-Corley; John F Engelhardt
Journal:  Sci Transl Med       Date:  2019-03-27       Impact factor: 17.956

7.  Predictive effects of low birth weight and small for gestational age status on respiratory and nutritional outcomes in cystic fibrosis.

Authors:  Samar E Atteih; Karen S Raraigh; Scott M Blackman; Garry R Cutting; Joseph M Collaco
Journal:  J Cyst Fibros       Date:  2020-02-12       Impact factor: 5.482

8.  Growth failure and treatment in cystic fibrosis.

Authors:  Trang N Le; Abeer Anabtawi; Melissa S Putman; Vin Tangpricha; Michael S Stalvey
Journal:  J Cyst Fibros       Date:  2019-10       Impact factor: 5.482

9.  Identification of CFTR variants in Latino patients with cystic fibrosis from the Dominican Republic and Puerto Rico.

Authors:  Andrew M Zeiger; Meghan E McGarry; Angel C Y Mak; Vivian Medina; Sandra Salazar; Celeste Eng; Amy K Liu; Sam S Oh; Thomas J Nuckton; Deepti Jain; Thomas W Blackwell; Hyun Min Kang; Goncalo Abecasis; Leandra Cordero Oñate; Max A Seibold; Esteban G Burchard; Jose Rodriguez-Santana
Journal:  Pediatr Pulmonol       Date:  2019-10-30

Review 10.  Novel imaging techniques for cystic fibrosis lung disease.

Authors:  Jennifer L Goralski; Neil J Stewart; Jason C Woods
Journal:  Pediatr Pulmonol       Date:  2021-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.